Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CASP6 | P55212 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049959 | 0.87 | NPSR1 (0.58) | CYP3A4TDP1MEN1KMT2APOLB | |
| SCHEMBL13292107 | 0.82 | PTPRC (0.55) | CYP3A4TDP1MEN1KMT2APOLB | |
| SCHEMBL27006367 | 0.79 | KMT2A (0.56) | CYP3A4TDP1MEN1KMT2APOLB | |
| SCHEMBL12568173 | 0.78 | MEN1 (0.55) | TDP1MEN1KMT2APOLBCASP6 | |
| SCHEMBL3276659 | 0.77 | ALDH1A1 (0.59) | TDP1MEN1KMT2APOLBCASP6 | |
| SCHEMBL151957 | 0.74 | CYP3A4 (1.00) | CYP3A4TDP1MEN1KMT2APOLB | |
| SCHEMBL11064297 | 0.74 | TDP1 (0.56) | CYP3A4TDP1MEN1KMT2AMAPT | |
| SCHEMBL7709452 | 0.74 | MEN1 (0.58) | TDP1MEN1KMT2APOLBCASP6 | |
| SCHEMBL27798142 | 0.73 | CYP3A4 (0.96) | CYP3A4TDP1MEN1KMT2APOLB | |
| Methane SCHEMBL28326322 | 0.73 | CYP3A4 (0.96) | CYP3A4TDP1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106749017-A | A kind of synthetic method of 1,8 naphthalimides of 3,6 halogen atoms substitution | 南昌大学 | 2017-05-31 | — | — | CN | claimed |
| US-4499266-A | MICROBIOCIDES AND ANTICARCINOGENIC | WARNER-LAMBERT COMPANY (US) | 1985-02-12 | — | — | US | claimed |
| CN-106749017-B | A kind of synthetic method for 1, the 8- naphthalimide that 3,6 halogen atoms replace | 南昌大学 | 2019-05-24 | — | — | CN | disclosed |
| CN-106749017-A | A kind of synthetic method of 1,8 naphthalimides of 3,6 halogen atoms substitution | 南昌大学 | 2017-05-31 | — | — | CN | disclosed |
| EP-1626050-B1 | SULFUR-CONTAINING NAPHTHOYLIMIDE DERIVATIVES | UNIV EAST CHINA SCIENCE & TECH (CN) | 2009-12-02 | — | — | EP | disclosed |
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-24 | — | — | US | disclosed |
| EP-1742920-A2 | NAPHTHALIMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Unibioscreen S.A. (BE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005105753-A2 | NAPHTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2005-11-10 | — | — | WO | disclosed |
| US-4499266-A | MICROBIOCIDES AND ANTICARCINOGENIC | WARNER-LAMBERT COMPANY (US) | 1985-02-12 | — | — | US | disclosed |
| US-4499266-A | MICROBIOCIDES AND ANTICARCINOGENIC | WARNER-LAMBERT COMPANY (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | NPM1, NAPRT, NUTF2 | CYP3A4 264/4885TDP1 2335/4885MEN1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.